For a U.S. dermatology Phase II trial in hidradenitis suppurativa, IQVIA Biotech designed a data-driven recruitment strategy to accelerate enrollment and reduce costs. Leveraging IQVIA CORE data, site clustering in diverse, densely populated, and southern regions optimized site access and media impact. Centralized recruitment combined traditional and digital outreach, patient advocacy, and physician referral programs. Continuous monitoring enabled adaptive tactics that maximized ROI and enrollment efficiency. The trial reached its enrollment goal two weeks early, with 40% of randomized subjects generated directly through recruitment efforts and nearly half of African American/Hispanic patients enrolled from targeted markets.

Join for free to read